Document:

EX-10.20

 Exhibit 10.20 

The Athenex Pharmaceutical Base Project 

Located in the Chongqing Maliu Riverside Development Zone 

Agreement 
 Chongqing
Maliu Riverside Development and Investment Co., Ltd. 
 October 16, 2015 

  
 1 

 Investment Agreement 

Party A: Chongqing Maliu Riverside Development and Investment Co., Ltd. (referred to below as Party A) 

Party B: Athenex, Inc. (referred to below as Party B) 

Article I — After carefully inspecting and investigating the investment environment associated with the Chongqing Maliu Riverside
Development Zone (referred to below as the Zone), Party B has determined to invest capital in the Zone for the construction of an Athenex Pharmaceutical Base (referred to below as the Project). Party A welcomes investment from Party B. Pursuant to
relevant State laws, regulations, and policies, and after thorough consultation, this Agreement is executed by and between the two parties in accord with the principles of equality, voluntariness, mutual benefit, and the pursuit of common
development. 
 Article II — The Project complies with State industrial policies, State environmental protection requirements, and the
overall planning and industrial planning of the Zone. The Project will feature the world’s most advanced innovative technologies with respect to new pharmaceutical R&D in the construction of a pharmaceutical manufacturing plant and active
pharmaceutical ingredient (API) plant, wherein: 
 The pharmaceutical manufacturing plant will be furnished with three oral preparation
technology platforms, i.e. Orascovery, Mimetica, and OPAL. The manufacturing plant will feature world-class pharmaceutical innovation platforms and 8 production lines for the formulation of high potency pharmaceuticals, and will manufacture drugs in
the form of high-level sterile injectables, oral dosages, and other formulations. 
 The API plant will be involved in the research,
development, and production of high value-added active pharmaceutical ingredients, including high potency oncology active pharmaceutical ingredients, which require low energy consumption and low emissions. From the day on which the plant
construction is completed, a “Pharmaceutical Production License” shall be obtained within 2 years, and domestic and international registration applications shall be completed for at least 10 products, including existing products Paclitaxel
and Docetaxel, within 5 years. In addition, provided that certification is obtained for compliance with the updated GMP 

  
 2 

 
regulations of the People’s Republic of China (“China”), the U.S. Food and Drug Administration (FDA), the European Directorate for the Quality Control of Medicines (EDQM), and the
Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and the requirements for all the active pharmaceutical ingredients and intermediates required for the drugs in connection with Party B’s pharmaceutical manufacturing platform are met,
the construction of an internationally renowned base for the research, development, production, and export of high potency oncology and other active pharmaceutical ingredients shall be completed within 10 years. 

Article III — The plot for the pharmaceutical manufacturing plant associated with the Project is located in the Mudong section of the
Zone and covers approximately 500 mu of land. The plot for the API production plant associated with the Project is located in the Maliu section of the Zone and covers approximately 45 mu of land. The final measurements shall be based on the limits
as demarcated by the red lines in the [land allocation] plan, and the land is intended for industrial use. Refer to the figure(s) attached for details. 

Article IV — The pharmaceutical manufacturing plant associated with the Project will cover a building area of 40,000 square meters, and
the API production plant will cover a building area of 20,800 square meters. The two will allow a differential increase of no more than 20%. For the construction plans (which include public facilities and decorations), upon approval from Party B and
relevant competent authorities in the industry, Party A will invest in the plant construction and will be responsible, with the assistance of Party B, for completing the decorations in accordance with U.S. CGMP standards. The work will conclude on
December 31, 2016. 
 Party A will exercise ownership rights over the land and buildings. Party A will not be required to pay rent for
the first 10 years. Once the term is up, Party B may continue renting for an additional 10 years. During the renewal period, if Party B achieves profitability, it shall pay rent once each year equivalent to RMB 5 per square meter of building area
per month; or it may purchase the property based on the cost of the land and plant construction, plus the appraised value of the decorations, plus annual interest based on the current benchmark interest rate for bank lending. If, after 20 years,
Party B has still not purchased the property for the cost of the land and plant construction (including decoration expenses) as set forth above, the property will be leased for the current market rate based on the building area. 

  
 3 

 Article V — Party B is responsible for the equipment, technology, and other investments.
Party B shall complete the equipment commissioning and launch production within 6 months of the day on which Party A delivers the plant to Party B, and production will officially launch within 12 months thereafter. 

Article VI — Party B shall achieve sales revenue of RMB 915 million in the second year after the Project is up and running. Within
10 years after the Project is up and running, sales revenue shall reach a cumulative total of RMB 52 billion, and value-added taxes (VAT), surtaxes, and income taxes shall reach a cumulative total of more than RMB 10 billion. See the
tables below for the specific sales revenues and tax amounts for each year (these figures allow a differential decrease of 20%): 
 Table 1:

 Estimated Sales Revenue (in RMB 10,000s) 
  

																																									
	 Year
	  	1st year	 	  	2nd year	 	  	3rd year	 	  	4th year	 	  	5th year	 	  	6th year	 	  	7th year	 	  	8th year	 	  	9th year	 	  	10th year	 
	 Manufacturing
	  	 	46500	 	  	 	156000	 	  	 	320000	 	  	 	432050	 	  	 	495872	 	  	 	543758	 	  	 	570670	 	  	 	587550	 	  	 	604937	 	  	 	622845	 
	 API
	  	 	45000	 	  	 	63000	 	  	 	81000	 	  	 	91000	 	  	 	93000	 	  	 	93000	 	  	 	93000	 	  	 	93000	 	  	 	93000	 	  	 	93000	 
	 Total
	  	 	91500	 	  	 	219000	 	  	 	401000	 	  	 	523050	 	  	 	588872	 	  	 	636758	 	  	 	663670	 	  	 	690550	 	  	 	697937	 	  	 	715845	 

 Table 2: 

Estimated Taxes (in RMB 1,000,000s) 
  

																																									
	 Year
	  	1st year	 	  	2nd year	 	  	3rd year	 	  	4th year	 	  	5th year	 	  	6th year	 	  	7th year	 	  	8th year	 	  	9th year	 	  	10th year	 
	 Total VAT and surtax
	  	 	56	 	  	 	187	 	  	 	384	 	  	 	518	 	  	 	595	 	  	 	653	 	  	 	685	 	  	 	705	 	  	 	726	 	  	 	747	 
	 Income tax
	  	 	9	 	  	 	50	 	  	 	114	 	  	 	157	 	  	 	183	 	  	 	200	 	  	 	210	 	  	 	217	 	  	 	223	 	  	 	230	 
	 Total
	  	 	65	 	  	 	237	 	  	 	498	 	  	 	675	 	  	 	778	 	  	 	853	 	  	 	895	 	  	 	922	 	  	 	949	 	  	 	977	 

 Article VII — Party A shall ensure that water supply, water discharge, natural gas (for clients requiring
the construction of a dedicated pipeline for high gas usage, Party A shall lend assistance to Party B in filing an application, and Party B shall assume the costs for the design and construction), communications, cable television, and broadband
network facilities are set up 1 meter outside the limits of Party B’s land allotment as demarcated by red lines, and the power lines shall be connected to a designated 10 kV switching station; further discussion will be required for power
levels exceeding 10 kV. Party B shall be solely responsible for fees associated with the water, electricity, natural gas, and other utility accounts as well as the construction and use thereof, and it shall pay the fees in a timely manner. In
addition to ensuring the water, power, and gas supply as set forth above, Party A undertakes to provide water, power, and gas at the best discounted rates. 

  
 4 

 Article VIII — Within 3 months of the signing of this Agreement, Party B will register a new
independent corporation in the Banan District, and it shall be responsible for the operation of the Project. The registered capital for the Project shall be no less than US $30 million (in cash contributions), and Party A shall assist with the
registration. The Project owner shall be responsible for performing all the obligations associated with the production and operation of the Project. If the Project owner fails to perform all obligations in accordance with this Agreement, Party B
shall be held jointly and severally liable for the legal consequences arising therefrom. The Project owner is required to declare taxes to the grassroots taxation authority and truthfully report statistical information to the service center with
jurisdiction over the area in which the Chongqing Maliu Riverside Development Zone is located. 
 Article IX — Within 30 business days
following the signing of this Agreement, Party B shall pay to Party A a performance bond in the amount of US $1 million. The performance bond shall be returned to Party B the day on which the Project is up and running, and no interest shall
accrue during the interim period. 
 Article X — Party B is required to obtain the written consent of Party A to transfer the Project,
unless said transfer is made to an affiliated Group Company under Athenex (i.e. a subsidiary of which Party B directly and/or indirectly owns no less than 50% of the equity or management rights, and/or a direct and/or indirect holding company of
Party B, and/or a subsidiary of which said direct and/or indirect holding company directly and/or indirectly owns no less than 50% of the equity or management rights; collectively referred to as “Group Company”). 

Article XI — Party B shall be entitled to preferential policies for the Project as follows: 

1. After [the Project] is confirmed by relevant departments to be included in the industries encouraged by the State, [Party B] shall be
entitled to the preferential policies for western Chinese development in accordance with applicable provisions, i.e. income taxes are reduced by 15% for enterprises engaged in western Chinese development. 

2. After Party B is confirmed to be a hi-tech enterprise, it shall be entitled to the relevant
preferential policies available for hi-tech enterprises in urban areas. 

  
 5 

 3. Party A shall lend assistance to Party B in applying for preferential policies from the
Chongqing municipality in various areas of the pharmaceutical industry including R&D, marketing, product import & export, and talent acquisition (including but not limited to making tax incentives or exemptions for a certain proportion
of income (including benefits) available to senior management of Party B which are located in Chongqing and/or assigned to Chongqing from another province and/or country). 

Article XII — Party B undertakes that, before the Project is up and running, it shall not construct or use any product production lines
which are of the same type as or related to the three oral preparation technology platforms of Orascovery, Mimetica, and OPAL in China. Party B shall be given priority negotiation rights for a maximum of 6 months for any other projects associated
with Party B’s products. 
 Article XIII — Default liability and withdrawal mechanism: 

1. Party A shall be considered in breach of contract if it fails to perform all the stipulations contained in this Agreement, in which case
Party B shall have the right to terminate this Agreement; Party A shall return to Party B the performance bond and pay to Party B the equivalent amount in liquidated damages. 

2. Party B shall be considered in breach of contract if it fails to perform all the stipulations contained in this Agreement, in which case
Party A shall have the right to terminate this Agreement, and Party A shall not return the performance bond. 
 3. If Party B fails to
achieve the sales revenue or annual tax amount as stipulated in Article 6 hereunder, Party A shall have the right to notify Party B in writing and require Party B to achieve the sales revenue or annual tax amount as stipulated in Article 6 within 2
years of the day on which such notice is provided. If Party B is still unable to achieve the sales revenue or annual tax amount as stipulated in Article 6 by the expiration of the term, Party A shall have the right to dispose of the plants at its
own discretion. 
 Article XIV — Party A shall actively assist in enrolling the Project as a municipal-level key projects, and shall
actively coordinate with relevant municipal bodies to provide applicable industry support policies. 
 Article XV — Miscellaneous: 

1. The two parties shall engage in separate discussion for laboratories and office spaces required during the early stages of the construction
for the Project. 

  
 6 

 2. If Party B intends to convert the Chinese construction into a medical center project, it
should give priority consideration to working with Party A and allow Party A to have priority negotiation rights for a period of 6 weeks. 

3. This Agreement shall be made in sextuplicate, with Party A, Party B, and the witnessing party each holding three copies carrying equal legal
effect. 
 4. For any matters not covered hereunder, Party A and Party B may enter into a supplemental agreement, which shall carry the same
legal effect as this Agreement. 
 5. Party A and Party B hereby irrevocably promise to the other party that they will do everything within
their power to keep as confidential the existence of this Agreement and/or any terms contained herein, and they further promise to the other party that, without the prior written approval of the other party, they shall not disclose to any third
party the existence of this Agreement and/or any terms contained herein, unless said disclosure is: 
 (i). Provided to their employees,
directors, advisors, bankers, and/or agents, and said person(s) and/or organization(s) have a corresponding confidentiality liability thereto; 

(ii). Related to any market launch of Party B and/or its affiliated Group Company; 

(iii). Provided for the purpose of complying with any applicable regulations and/or guidelines in China locally and/or in other provinces
and/or countries (including but not limited to rules for securities listings); 
 (iv). Already public information due to (ii) or (iii)
as shown above. 
 Party A and Party B agree and undertake that they shall not unreasonably and intentionally delay and/or refuse the
submission of said prior written consent. Party A and Party B agree and undertake that the confidentiality liabilities described above shall continue to be executed and remain in effect upon the termination of this Agreement. 

6. This Agreement shall be governed by relevant Chinese legislation and shall be construed accordingly. 

7. Any disputes arising in connection with this Agreement during the execution hereof should be resolved through consultation. Should such
consultation fail, the two parties may initiate and carry out arbitration proceedings remotely (in Shenzhen) pursuant to the rules of arbitration of the China International Economic and Trade Arbitration Commission (CIETAC) in place and in force at
the time the application for arbitration is filed. The arbitral award shall be final and binding on the two parties. 

  
 7 

 8. Party A 

    Address: Technology Incubation Building, Mudong Town, Banan District, Chongqing 

    Fax no.: +86-23-86953595 

    Recipient: Peng Yong 

    Party B 

    Address: 701 Ellicott Street Buffalo New York 

                14203 USA; 

                    or beginning
October 26, 2015 

                    Conventus Building 1001
Main Street Sixth 
                 Floor Buffalo, New York
14203 USA 
     Fax no.: +716-898-8588

     Recipient: Flint D. Besecker 

    Copies to be delivered to: Comprehensive Drug Enterprises Limited 

                        
                  Units 608-613, No. 6 Science Park West Avenue, 

                        
                  Hong Kong Science Park, Sha Tin, Hong Kong 

    Fax no.: +852 3996 7454 

    Recipient: Yang Yikuang 

Unless otherwise stipulated, Party A and Party B agree to make contact using the addresses and fax numbers provided above. 

9. This Agreement shall take effect once it is signed and sealed by Party A, signed by Party B, and Party B reaches US $4 million in
registered capital and pays the performance bond in full. 
 (There is no main text below) 

  
 8 

					
	Party A: Chongqing Maliu Riverside    	  	Party B: ATHENEX, INC.
	Development and Investment Co., Ltd.	  	
	(signature and seal)    	  	 [Seal: Chongqing Maliu
 Riverside Development
and
 Investment Co., Ltd. [illegible]]
	  	

		
	Representative: [Signature: [illegible]]	  	Representative: Flint D. Besecker

                       
 Place signed: Chongqing 

                    Date signed:
October 16, 2015 

  
 9EX-10.21

 Exhibit 10.21 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

Confidential Materials omitted and filed separate with the Securities and Exchange Commission 

Triple asterisks denote omissions 
  

 
 NANG KUANG PHARMACEUTICAL CO., LTD 

December 29, 2016 
 VIA
E-MAIL 
 Athenex API limited 

Hong Kong 
  

	Re:	Binding Term Sheet — Pemetrexed License and Distribution 

 To whom it may concern, 

This binding term sheet (this “Term Sheet”) contains the basic terms that the Parties hereto may incorporate into a definitive
License, Supply and Distribution Agreement (the “Definitive Agreement”) to be negotiated by and between Athenex API Limited (“Athenex”) organized under the law of Hong Kong on the one hand and Nang-Kuang, Pharmaceutical
Co., LTD (“NK”) organized under the law of Taiwan and CANDA NK-2, LLC (“CANDA”) organized under the law of Texas on the other hand (Athenex, NK and CANDA are each sometimes individually
referred to herein as a “Party” and collectively the “Parties”) for the Product (as defined below). The proposed transaction is subject to due diligence by Athenex and the negotiation, execution, signature and delivery of the
Definitive Agreement and any other agreements related thereto. With this understanding, please either respond with any objections, corrections, and suggested revisions to the proposed terms, or acknowledge your desire to move forward in the
negotiations generally as set forth herein by signing and returning a copy of this letter. 
 GENERAL TERMS: 

 

	 Product: 
	Pemetrexed Disodium Injection, the generic equivalent of Alimta®, in 100mg and 500mg presentations as described in ANDA No. 207352 (the “Regulatory Submission”).

  

	 Territory: 
	The United States of America, including all of its possessions, territories and dependencies. 

  

	 Term/Termination: 
	 The term of the Definitive Agreement shall commence on the date of complete execution of the Definitive Agreement and continue for a period of ten
(10) years from the date of the first commercial sale of the Product in the Territory by Athenex (the “Initial Term”), which shall automatically renew for successive two (2) year periods (each a
“Renewal Term” and 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

	 	 
together with the Initial Term, the “Term”), unless either Party delivers written notice to the other Party, at least six (6) months prior to the expiration of the Initial Term or
any Renewal Term, of its election not to renew the Definitive Agreement. 

  

	 	The Definitive Agreement may be terminated prior to the expiration of the Term for reasons including, but not limited to, the following: 

 

	 	(a)	Athenex may terminate, immediately upon written notice to NK, if NK materially breaches any of the terms of the Quality Agreement to be executed by the Parties. 

 

	 	(b)	Either Party may terminate upon sixty (60) days prior written notice if the other Party materially breaches any of its covenants, representations or warranties contained or incorporated by reference in the
Definitive Agreement and such breach is not cured within such 60-day period after receiving written notice of the breach from the other Party. 

 

	 	(c)	Either Party may terminate immediately upon written notice to the other Party in the event that the other Party: (i) is or becomes insolvent; (ii) files, or has filed against it, a petition in bankruptcy,
insolvency, liquidation or dissolution of assets, which, in the case of a petition filed against it, has not been dismissed within ninety (90) days; (iii) fails generally to pay its debts as they become due or admits in writing its inability to
pay its debts; (iv) makes any assignment for the benefit of creditors; (v) has appointed a receiver of its property or a substantial portion thereof; or (vi) voluntarily takes advantage of any other law or procedure for the protection
of debtors. 

  

	 	(d)	Athenex may terminate upon thirty (30) days prior written notice to NK in the event the Transfer Price Formula B calculation (described below) results in an amount equal to or less than zero, and the Parties are
unable to reach agreement on reductions to the actual cost of the Products to Athenex’s satisfaction. 

  

	 Development: 
	NK has completed the development of the Product according to current Good Manufacturing Practices (“cGMPs”) and filed the Regulatory Submission with the FDA for the commercialization of the Product in the Territory, which Regulatory
Submission is pending approval from the FDA. 

  

	 Supply: 
	NK shall be responsible, at its expense, for the following: (i) ensuring that the Product is manufactured according to cGMPs and (ii) ensuring that any facility or facilities used in the manufacture of the Product (each a
“Facility”) is prepared for and ready to pass FDA inspections, and are, at all times designed, maintained, operated and updated as necessary to ensure compliance with cGMPs and in fact remain so compliant. 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 2 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

 Ownership; 

License; 

	 Regulatory Fees: 
	All right, title and interest in the Regulatory Submission is currently owned by NK. Notwithstanding the foregoing, NK/CANDA will grant to Athenex an exclusive, royalty-free, non-cancellable, sub-licensable license in and to all intellectual property, know-how and any other proprietary rights associated with the Product and the Regulatory Submission for the Product
to promote, use, sell, have sold, offer for sale, market, distribute, import and otherwise commercialize the Product in the Territory (the “License”). Subject to the terms of the License, Athenex shall have the sole and absolute discretion
as to all matters pertaining to the promotion, marketing, sale and commercialization of the Product in the Territory. Athenex would be responsible for determining the price to advertise and charge its customers for the Product in its sole
discretion. Each Party shall cooperate with the other Party and shall provide each other with all support reasonably requested by the other Party in connection with the maintenance of such Regulatory Submission. NK/CANDA shall be responsible for
maintaining the Regulatory Submission associated with the Product, and shall pay all GDUFA or other fees, costs and expenses associated with the Regulatory Submission. 

 

	 Exclusive Supply: 
	NK/CANDA would appoint Athenex as its sole and exclusive distributor for marketing and selling or otherwise commercializing the Product in the Territory. During the Term, NK/CANDA shall not market, distribute, sell or supply the Product in the
Territory, nor shall NK/CANDA appoint, license, authorize, or permit any party other than Athenex or Athenex’s designee, as the case may be, to market, distribute, sell, or supply the Product in the Territory. In addition, NK/CANDA would not
sell or supply Product to any person or entity that NK/CANDA knows or reasonably should know intends to resell the Product in the Territory. Athenex shall purchase all of its requirements for the Product from NK based upon Transfer Price Formula A
(defined below), subject to NK’s ability to meet Athenex’s forecasted requirements, and Athenex shall be entitled to maintain a qualified back up source for the Product in the event of a failure of NK to supply the Product without
prejudice to any other rights available to NK under this term sheet and applicable law including the rights provided in the Financial Terms section of this term sheet. For the avoidance of doubt, in the event that Athenex obtains Product from such
back up supplier, Athenex would not be required to make any Second Payments (as defined below) to NK in connection with such Product. 

  

	 Labeling, Marketing: 
	 The Product would be marketed on a private label basis under the “Athenex” brand. Athenex would design the label for the Product and

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 3 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

	 	 
market the Product in its sole discretion, subject to applicable law, and would be responsible for all regulatory submissions required in connection with such labeling and marketing. NK would
label the Product in accordance with Athenex’s instructions, and Athenex would provide to NK all materials necessary for such labeling, including designs and artwork. All intellectual property created, generated, developed, or derived by or on
behalf of Athenex in connection with the labeling and marketing of the Product would be the exclusive property of Athenex. 

  

	 Third Party Infringement Claims: 
	If any third-party claim, demand, or cause of action (“Action”) claiming patent infringement arises out of or results from the Regulatory Submission or sale of the Product by Athenex in the Territory, the Parties shall jointly defend
and control any such action by counsel mutually acceptable to the Parties, and the legal fees and related costs and expenses of such defense (“Defense Costs”) shall be paid by Athenex. Athenex shall have the right, but not the obligation,
at its sole expense to retain separate counsel in defense of any third-party claim of patent infringement relating to the Regulatory Submission or sale of the Product. Without limiting the foregoing, Athenex shall indemnify and hold harmless NK and
CANDA for any damages resulting from any Action made or brought against NK/CANDA by any third party as a result of (a) any negligent act or omission or intentional misconduct of Athenex in relation to its obligations under the Definitive
Agreement to market and sell the Product in the Territory; (b) any breach of the Definitive Agreement by Athenex; or (c) any infringement of any third party patent based upon the sale of the Product by Athenex in the Territory.
Notwithstanding the foregoing, in the event that Athenex incurs any Defense Costs, and/or a third-party infringement claim results in a settlement or a final, non-appealable judgment that Athenex’s sales
of the Product infringe at least one valid claim of a third-party patent and Athenex is required to make any payments as a result of such settlement or judgment (“Infringement Payments”), or Athenex is obligated to indemnify NK/CANDA for
any damages or other losses resulting from Athenex’s sale of the Product in the Territory (“Indemnification Payments”), Athenex would be entitled to keep and retain 100% of the Transfer Price Formula B from sales of the Product (i.e.,
the Third Payment would be eliminated going forward) until after the later of (y) the respective patent expires, and (z) the amount of Transfer Price Formula B retained by Athenex equals the sum of any Defense Costs, Infringement Payments
and Indemnification Payments. 

  

	 	 NK/CANDA would indemnify, defend, and hold Athenex harmless from and against all damages, liabilities, obligations,
settlements, costs and expenses, including reasonable legal fees (collectively, “Damages”) 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 4 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

	 	 
incurred by Athenex arising in connection with any Action made or brought against Athenex by any third party as a result of (a) any negligent act or omission or intentional misconduct of
NK/CANDA in relation to its obligations under the Definitive Agreement to manufacture and supply the Product to Athenex, (b) any breach of the Definitive Agreement by NK/CANDA, or (c) any alleged or actual defects in the Product supplied
by NK/CANDA to Athenex. 

  

	 Stoppage: 
	Athenex would have the right, without liability, to suspend its obligations to market and sell the Product under the Definitive Agreement in the event (i) of an injunction or other court order being issued which prohibits or restricts the
marketing or sale of the Product in the Territory, (ii) the FDA or another applicable regulatory authority prohibits or restricts the marketing or sale of the Product in the Territory, or (iii) Athenex becomes aware of any potential
adulteration, misbranding and/or other issues regarding the safety of the Product. 

  

	 Launch Date: 
	Athenex shall utilize its commercially reasonable efforts to launch the Product within ten (10) days of the lifting or dissolution of the preliminary injunction entered in Case No. 1:14-CV-1647-TWP-DKL (“Pending Litigation”) currently pending in the United States District Court for the Southern
District of Indiana, Indianapolis Division (“Preliminary injunction”); provided there are no external barriers to Athenex’s launch of the Product (i.e. regulatory approval, manufacturing, inventory, or legal proceeding). In the event
that (i) the Preliminary Injunction has been lifted or dissolved, (ii) the Regulatory Submission has final FDA approval; (iii) there is sufficient launch inventory available to Athenex to supply at least 10% of the market in the
Territory; (iv) there are no other external barriers to Athenex’s launch of the Product; and (v) Athenex, in its sole discretion, refuses to launch the Product within such ten (10) day period, Athenex shall provide NK with
written notice of its intent not to launch the Product and, within thirty (30) days of receipt of such notice, NK/CANDA shall be entitled to terminate the Definitive Agreement and the License to the Product associated therewith. In such event,
Athenex shall transfer to NK free and clear title to any commercial launch quantities produced pursuant to Purchase Orders (defined below) submitted by Athenex, provided that Athenex shall be responsible for paying NK/CANDA any outstanding amounts
owed under said Purchase Orders. Moreover, all Prepayments paid by Athenex shall be retained by NK/CANDA. Nothing in this term sheet shall require Athenex to launch the Product prior to a finding of unpatentability by the Patent Trial and Appeal
Board in any combination of IPR2016-00237, IPR2016-00240 and IPR2016-00318 of all claims that the Parties reasonably determine the Product infringes. 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 5 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

 Purchase Orders; 

	 Forecasts: 
	Athenex will purchase the Product from NK by submitting purchase orders which will include the quantity (which must be multiples of the validated batch size), delivery information (including destination) and desired delivery date (each a
“Purchase Order”). Purchase Orders for the initial commercial launch quantities of Product shall be submitted to NK no less than one-hundred and eighty (180) days prior to the requested delivery
date and Purchase Orders for subsequent quantities of Product shall be submitted to NK no less than ninety (90) days prior to the requested delivery date. Athenex shall provide forecast estimates (each a “Forecast”) to NK of its
supply needs of the Product at least ninety (90) days prior to the submission of a Purchase Order to allow NK sufficient time to acquire API and other required supplies. NK shall review and reasonably approve the Forecasts and Purchase Orders.
Upon NK’s approval of a Purchase Order, (i) NK shall be obligated to supply to Athenex the quantities of the Product within the time frames required pursuant to the relevant Forecasts and Purchase Orders; and (ii) Athenex shall pay to
NK the Second Payment of the Transfer Price as defined in the section of Financial Terms below within 30 days thereafter. If the quantity of the Product requested in a Purchase Order is increased by more than ten percent (10%) compared to the most
recently submitted Forecast, then NK shall use commercially reasonable efforts to supply such increased amount to Athenex; however, NK shall not be subject to any penalty if it is unable to supply such increased amount. If the quantity of the
Product requested is lower than the forecast, resulting in the waste of API and other supplies, Athenex will be responsible for the cost of any wasted materials, including API. In furtherance of the foregoing, Athenex anticipates placing Purchase
Orders in Q1 2017 to establish necessary inventory to support commercial launch. 

  

	 	*** 

  

	 Shipping: 
	NK shall pay for shipping (shipments to be made FOB Destination (Incoterms 2010)) and will be liable and responsible for any loss or damage while shipments FOB are in transit. 

 

	 Publicity: 
	 The Parties agree that there will be no press release or other public statement issued by either Party relating to this Term Sheet without the written
consent of the other Parties, which consent may be withheld in the absolute discretion of any Party. Notwithstanding the foregoing, in the event either Party is required by applicable law (as determined by counsel of such Party) to make a public
disclosure, the Parties shall cooperate and agree on the language of such disclosure. Nothing in this paragraph shall preclude NK from making all necessary public disclosures required by its listing on the Taiwan Stock Exchange (“Press
Release”). Athenex shall have the right to review the Press Release prior to publication. NK shall 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 6 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

	 	 
engage in good faith negotiations with Athenex regarding the content of the Press Release in the event that Athenex objects to the content of the Press Release. 

 

	 Confidentiality: 
	NK, CANDA and Athenex are parties to a Confidential Disclosure Agreement dated as of December 13, 2016 (the “Confidentiality Agreement”), which includes obligations of the Parties to maintain in confidence all Confidential
Information (as defined in the Confidentiality Agreement) of the other Parties, and the Parties agree that the terms of the Confidentiality Agreement shall not be amended, supplemented, abridged or terminated by this Term Sheet. The Confidentiality
Agreement shall apply to the terms contained in this Term Sheet and the information exchanged by the Parties in connection with the negotiations and/or discussions regarding this Term Sheet. 

 

	 ***: 
	*** 

  

	 Governing Law: 
	This Term Sheet and the Definitive Agreement shall be governed by the laws of the state of Delaware, without regard to conflict of law provisions. 

  

	 Miscellaneous: 
	The Parties will make good faith efforts to execute the Definitive Agreement within sixty (60) days of the execution of this Term Sheet. The Parties acknowledge that the terms set forth in this Term Sheet are not exhaustive and the
Definitive Agreement shall include such other terms as are customary in a transaction of this nature, including such representations, warranties, covenants and insurance and indemnification obligations as shall be mutually agreed to by the Parties.

 FINANCIAL TERMS: 
 Transfer
Price: Overview (Components of the Transfer Price). Athenex would purchase the Product from NK at a transfer price (“Transfer Price”) to be agreed upon by both Parties. The Transfer Price would be divided into three types of
payments: (1) one, two or three prepayments as specified in a below (collectively referred to as the “Prepayments”), (2) a payment after confirmation of each Purchase Order (the “Second Payment”), and (3) a
payment after delivery of the Product pursuant to each Purchase Order (the “Third Payment”). 
  

	 	a.	Prepayments 

 Athenex is required to make the First Prepayment and Second Prepayments as
indicated below. The First Prepayment and Second Prepayment are not refundable or conditioned on any event other than the execution of this Term Sheet. All amounts specified herein are in US dollars. 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 7 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

	 	•	 	$3,000,000 upon execution of this Term Sheet between NK/CANDA and Athenex (“First Prepayment”); to be paid no later than twenty (20) business days after the execution of this Term Sheet; and

  

	 	•	 	$9,000,000 on or before May 1, 2017 (“Second Prepayment”). The Athenex agreement to make the Second Prepayment is a binding and irrevocable obligation and not conditioned on the occurrence of any other
event(s). For purposes of clarity and without the intent of being exhaustive, Athenex’s Second Prepayment obligation is not dependent in any manner on (1) the ability of Athenex to complete an initial public offering; (2) tentative or
final approval by the FDA of the Regulatory Submission; (3) the outcome in case 15-2067 at the United States Court of Appeals for the Federal Circuit; or (4) the outcome at the Patent Trial and
Appeal Board or any appeal in any of IPR2016-00237, IPR2016-00240 and IPR2016-00318.  Athenex is a sophisticated party in the business of developing pharmaceutical products and has the benefit of counsel experienced in pharmaceutical
industry transactions, patent law and Hatch-Waxman litigation when negotiating this Term Sheet. Further,  Athenex fully understands that there is risk associated with this transaction and events may transpire that make this a less
commercially attractive opportunity. Despite this, Athenex is willing to enter into this binding agreement via this Term Sheet and irrevocably agrees to make the Second Prepayment on or before May 1, 2017. In the absence of Athenex’s
commitment to make the Second Prepayment on or before May 1, 2017, NK/CANDA would not have entered into this Term Sheet with Athenex. 

  

	 	b.	Second Payment 

 Athenex shall make a Second Payment of the Transfer Price to NK for the
Product within thirty (30) days after NK’s confirmation of acceptance of each of Athenex’s Purchase Orders. The parties acknowledge that the amount of the Second Payment is based on ***% of the Transfer Price Formula A (defined
below). The “Transfer Price Formula A” means the actual cost that will be incurred by NK to produce and ship the Product, including but not limited to the cost of materials, labor, overhead, relevant insurance and shipping incurred by NK,
without any markup. The amount of the Transfer Price Formula A is estimated to be $ *** per 100 mg vial of the Product and $ *** per 500 mg vial of the Product, subject to the adjustment based on the Transfer Price Formula A that is to be determined
by the average of the first three batches for the first year and thereafter by the first batch annually for the following years. Upon request by Athenex, NK would provide Athenex the breakdown and supporting documentation how the Transfer Price
Formula A is calculated, and Athenex would have the right to audit NK’s books and records relating to the Transfer Price Formula A, limited once per year at Athenex’s sole cost. 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 8 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

	 	c.	Third Payment 

 Subject to the terms below, Athenex shall make a Third Payment to
NK/CANDA as a part of the Transfer Price equal to ***% of the “Transfer Price Formula B” (as defined below), which shall result in a ***% of Transfer Price Formula B to Athenex upon commercial launch of the Product. In addition, the total
amount of the Second Payment and Third Payment to NK/CANDA is ***% of the Transfer Price Formula A plus ***% of Transfer Price Formula B. If the Transfer Price Formula B calculation results in an amount equal to or less than zero, the Parties would
meet to negotiate how to reduce the actual cost of the Product. The Third Payment would be made on a quarterly basis by Athenex to NK/CANDA, within thirty (30) days following the end of each calendar quarter following the Launch Date. Each
payment would be accompanied by a statement showing the aggregate Net Sales of the Product for the applicable quarter, the aggregate cost incurred by Athenex for the units sold, and the calculation of the Third Payment. The following definitions
would apply to the calculation of the Third Payment: 
  

	 	(1)	“Athenex Profit” shall mean fifty percent (***%) of Transfer Price Formula B derived from Athenex’s sales of the Product in the Territory. 

 

	 	(2)	“Transfer Price Formula B” shall mean Net Sales less (i) the Second Payment to NK, freight in, duty, customs, shipping, inventory and write offs incurred by Athenex; and (ii) for the three
(3) year period following the execution of the Definitive Agreement, ***% of Net Sales (defined below) for Athenex’s costs related to marketing and selling the Product, and for the period beginning immediately after the expiration of the
three (3) year period following the execution of the Definitive Agreement, ***% of Net Sales (defined below) for Athenex’s costs related to marketing and selling the Product. 

 

	 	(3)	“Net Sales” shall mean the gross invoiced sales of the finished Product to all customers less (i) chargebacks; (ii) freight and insurance charges; (iii) trade discounts, credits or allowances;
(iv) costs of replacements, returns, recalls or rebates (including but not limited to group purchasing organization fees and rebates); (v) discounts or rebates or other payments required by law to be made under Medicaid, Medicare or other
governmental special medical assistance programs; (vi) wholesaler service charges; (vii) sales, excise or value added taxes paid on or in relation to sales of the finished Product and (viii) penalties from hospitals due to
insufficient Product supply caused by NK’s limited capacity; (ix) storage costs/fees; and (x) any other fees paid or costs incurred by Athenex in connection with the handling, storage, shipment, distribution and sale of the Product
(excluding marketing costs). All of the foregoing would be as calculated in accordance with United States Generally Accepted Accounting Principles. 

*** 
 *** 

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 9 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

 Athenex shall reasonably cooperate with NK to make all Transfer Price payments to NK in the
manner specified by NK and set forth in the Definitive Agreement between the Parties. 
 Accounting 

	 Rights: 
	Each Party shall have the right, no more than once per calendar year, to inspect the books and records of the other Parties to evaluate reported costs, including Transfer Price, Net Sales and Athenex Profit The Party requesting the audit shall
bear its costs. 

  

	 Expenses: 
	Each Party will bear its own legal, accounting and other fees and expenses related to the proposed business transaction incurred through the execution of the Definitive Agreement. 

 

	 Assignment: 
	The Definitive Agreement is not assignable by either Party without the prior written consent of the other Party hereto, which consent shall not be unreasonably withheld, delayed or conditioned. Notwithstanding the foregoing, either Party may
assign all or any portion of this Agreement without the consent of the other Party to an affiliate or upon a merger, reorganization or sale of substantially all its assets to which the Definitive Agreement relates. Without limiting the forgoing, NK
may assign all or any portion of the Definitive Agreement to CANDA. 

  

			
	Sincerely,
	
	NANG KUANG PHARMACEUTICAL CO., LTD
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

 

			
	Athenex API limited
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 10 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

			
	CANDA NK-2, LLC
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 11 

			
	

	  	  
 NANG KUANG PHARMACEUTICAL CO., LTD

 

 
			
	Sincerely,
	
	NANG KUANG PHARMACEUTICAL CO., LTD
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

 

			
	Athenex API limited
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

 

			
	CANDA NK-2, LLC
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

  
 *** = Portions of this exhibit
have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]